MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.360
+0.195
+6.16%
After Hours: 3.360 0 0.00% 19:37 05/27 EDT
OPEN
3.280
PREV CLOSE
3.165
HIGH
3.380
LOW
3.190
VOLUME
21.95K
TURNOVER
0
52 WEEK HIGH
15.72
52 WEEK LOW
3.020
MARKET CAP
43.74M
P/E (TTM)
-0.4279
1D
5D
1M
3M
1Y
5Y
Astria TherapeuticS GAAP EPS of -$1.18 misses by $0.45
Astria TherapeuticS press release (NASDAQ:ATXS): Q1 GAAP EPS of -$1.18 misses by $0.45. As of March 31, 2022, Astria had cash, cash equivalents and short-term investments of $112.8 million, compared
Seekingalpha · 05/12 20:47
Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference
BOSTON, April 21, 2022--Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological disease...
Business Wire · 04/21 12:00
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 04, 2022--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases...
Business Wire · 04/04 12:00
(ATXS) - Analyzing Astria Therapeutics Inc. - Common Stock's Short Interest
Astria Therapeutics Inc. - Common Stock's (NASDAQ:ATXS) short percent of float has fallen 18.83% since its last report. The company recently reported that it has 150.40 thousand shares sold short, which is 1.25% of all regular shares that are available for...
Benzinga · 03/21 13:15
Astria TherapeuticS GAAP EPS of -$0.73
Astria TherapeuticS press release (NASDAQ:ATXS): Q4 GAAP EPS of -$0.73. As of December 31, 2021, Astria had cash, cash equivalents and short-term investments of $125.5 million, compared to $131.8 million
Seekingalpha · 03/10 22:52
Astria Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, March 09, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that the Company will be participating in two upcoming investor conferences:
Business Wire · 03/09 13:00
Astria Therapeutics To Present STAR-0215 Data At 2022 American Academy of Allergy, Asthma And Immunology Annual Meeting Feb. 28
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share new preclinical data for STAR-0215 in a
Benzinga · 02/18 13:01
Astria Therapeutics to Present STAR-0215 Data at the 2022 American Academy of Allergy, Asthma and Immunology Annual Meeting
BOSTON, February 18, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share new preclinical data for STAR-0215 in a presentation t...
Business Wire · 02/18 13:00
More
No Data
Learn about the latest financial forecast of ATXS. Analyze the recent business situations of Astria Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

80.00%Strong Buy
20.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATXS stock price target is 21.60 with a high estimate of 30.00 and a low estimate of 13.00.
High30.00
Average21.60
Low13.00
Current 3.360
EPS
Actual
Estimate
-8.80-6.60-4.40-2.20
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 49
Institutional Holdings: 8.97M
% Owned: 68.91%
Shares Outstanding: 13.02M
TypeInstitutionsShares
Increased
7
69.42K
New
6
396.85K
Decreased
8
276.52K
Sold Out
6
72.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Co-Founder/Director
Jill Milne
Chief Financial Officer
Noah Clauser
Chief Scientific Officer
Andrew Nichols
Other
Benjamin Harshbarger
Other
Andrew Komjathy
Independent Director
Joanne Beck
Independent Director
Fred Callori
Independent Director
Hugh Cole
Independent Director
Michael Kishbauch
Independent Director
Gregg Lapointe
Independent Director
Jonathan Violin
No Data
No Data
About ATXS
Astria Therapeutics, Inc., formerly Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE.

Webull offers kinds of Astria Therapeutics Inc stock information, including NASDAQ:ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.